沙格雷酯

Sarpogrelate

未知生产厂商

Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.

适应症

用于改善慢性动脉闭塞症所引起的溃疡、疼痛及冷感等缺血性症状。

技术标识符

化学式: C₂₄H₃₁NO₆
CAS 编号: 125926-17-2
UNII ID: 19P708E787

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US 7893050 B2申请人: ASAHI KASEI PHARMA CORP优先权: 2005
US
WO
6 件公开
SARPOGRELATE FOR USE IN A METHOD FOR THE TREATMENT OF HEART DISEASE IN MAMMALS
EP 3609486 B1申请人: CEVA SANTE ANIMALE优先权: 2017
CN
EP
US
3 件公开
COMPLEX COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS INCLUDING SARPOGRELATE AND VACCINIUM MYRTILLUS EXTRACT AS ACTIVE INGREDIENTS
US 2024173372 A1申请人: IMDPHARM INC优先权: 2021
CN
US
WO
3 件公开
Controlled Drug-Release Composition and Drug-Releasable Medical Device
US 2009048667 A1申请人: UNIV TOKAI EDUCATIONAL SYSTEM优先权: 2005
CN
US
2 件公开
COMPOSITION, CONTAINING SARPOGRELATE AS ACTIVE INGREDIENT, FOR PREVENTING OR TREATING SENSORINEURAL HEARING LOSS
EP 3610869 A4申请人: AJOU UNIV INDUSTRY ACADEMIC COOPERATION FOUNDATION AND TECHNOLOGY优先权: 2017
EP
US
2 件公开
Use of serotonergic drugs to treat virus-induced thrombocytopenia
US 11426408 B2申请人: NAT UNIV SINGAPORE优先权: 2017
CN
US
2 件公开
Synthetic method of sarpogrelate hydrochloride intermediate 2-(3-dimethylamino-2-hydroxy) propoxybenzaldehyde
CN 114394905 A申请人: ANHUI PHARMACY CO LTD优先权: 2019
CN
2 件公开
Miniaturization sarpogrelate hydrochloride oral drug-giving preparation
CN 1903182 B申请人: MITSUBISHI TANABE PHARMA CORP优先权: 2005
CN
Controlled drug release composition and drug releasing medical device
CN 101309706 A申请人: UNIV TOKAI EDUCATIONAL SYSTEM优先权: 2005
CN
Sarpogrelate hydrochloride single layer osmotic pump regulated-release preparations and preparation thereof
CN 101259112 A申请人: FIRST AFFILIATED HOSPITAL OF W优先权: 2008
CN

药物